PL411543A1 - An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B. - Google Patents

An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B.

Info

Publication number
PL411543A1
PL411543A1 PL411543A PL41154315A PL411543A1 PL 411543 A1 PL411543 A1 PL 411543A1 PL 411543 A PL411543 A PL 411543A PL 41154315 A PL41154315 A PL 41154315A PL 411543 A1 PL411543 A1 PL 411543A1
Authority
PL
Poland
Prior art keywords
dna vaccine
dna
agent
kappa
virus
Prior art date
Application number
PL411543A
Other languages
Polish (pl)
Other versions
PL231230B1 (en
Inventor
Agnieszka Sirko
Anna Góra-Sochacka
Włodzimierz Zagórski-Ostoja
Anna Stachyra
Patrycja Redkiewicz
Patrick Midoux
Chantal Pichon
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL411543A priority Critical patent/PL231230B1/en
Priority to PCT/PL2015/000112 priority patent/WO2016144194A1/en
Priority to EP15745258.2A priority patent/EP3268033A1/en
Publication of PL411543A1 publication Critical patent/PL411543A1/en
Publication of PL231230B1 publication Critical patent/PL231230B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Abstract

Przedmiotem wynalazku jest czynnik zwiększający efektywność szczepionki DNA skierowanej przeciw wirusowi, preparat plazmidowy DNA, szczepionka DNA, sposób otrzymywania zmodyfikowanego wektora ekspresyjnego 3NF?B oraz ujawnia zastosowanie w szczepionce DNA sekwencji rozpoznawanej przez jądrowy czynnik transkrypcyjny NF kappa B (NF?B) w celu zapewnienia efektywnego transportu plazmidu szczepionkowego do jądra oraz podwyższenia poziomu transkrypcji wprowadzanego genu kodującego wybrany antygen.The present invention relates to a factor that increases the efficiency of a DNA vaccine directed against a virus, a DNA plasmid preparation, a DNA vaccine, a method for obtaining a modified 3NF-B expression vector, and discloses the use in a DNA vaccine of a sequence recognized by the NF kappa B nuclear transcription factor (NF-B) to provide efficiently transporting the vaccine plasmid to the nucleus and increasing the transcription level of the introduced gene encoding the selected antigen.

PL411543A 2015-03-11 2015-03-11 An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B. PL231230B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL411543A PL231230B1 (en) 2015-03-11 2015-03-11 An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B.
PCT/PL2015/000112 WO2016144194A1 (en) 2015-03-11 2015-07-09 A factor increasing efficiency of a dna vaccine against a virus, a plasmid dna formulation, a dna vaccine, a method of obtaining a modified expression vector and use of a nucleotide sequence recognised by the nf kappa b factor
EP15745258.2A EP3268033A1 (en) 2015-03-11 2015-07-09 A factor increasing efficiency of a dna vaccine against a virus, a plasmid dna formulation, a dna vaccine, a method of obtaining a modified expression vector and use of a nucleotide sequence recognised by the nf kappa b factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL411543A PL231230B1 (en) 2015-03-11 2015-03-11 An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B.

Publications (2)

Publication Number Publication Date
PL411543A1 true PL411543A1 (en) 2016-09-12
PL231230B1 PL231230B1 (en) 2019-02-28

Family

ID=53773481

Family Applications (1)

Application Number Title Priority Date Filing Date
PL411543A PL231230B1 (en) 2015-03-11 2015-03-11 An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B.

Country Status (3)

Country Link
EP (1) EP3268033A1 (en)
PL (1) PL231230B1 (en)
WO (1) WO2016144194A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023542132A (en) * 2020-09-16 2023-10-05 ジェネレーション バイオ カンパニー Non-viral DNA vectors and their use for expressing FVIII therapeutics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002329034A1 (en) * 2001-09-17 2003-04-01 Yeda Research And Development Co. Ltd. Nucleic acid constructs for the delivery of polynucleotides into dna-containing organelles,and uses thereof
EP2735614A1 (en) * 2012-11-22 2014-05-28 Centre National De La Recherche Scientifique In vitro production of DNA minicircles comprising less than 250 base pairs

Also Published As

Publication number Publication date
PL231230B1 (en) 2019-02-28
EP3268033A1 (en) 2018-01-17
WO2016144194A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
CY1124845T1 (en) METHODS OF DELIVERING MONOCLON RNA
HK1253540A1 (en) Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method
HK1256888A1 (en) Method for converting monocot plant genome sequence in which nucleic acid base in targeted dna sequence is specifically converted, and molecular complex used therein
MX2018004916A (en) Broad spectrum influenza virus vaccine.
PH12018500855A1 (en) Herpes simplex virus vaccine
IL253356A0 (en) Facilitating sending, receiving, and updating of payments using message and payment queues
MX2022006652A (en) Modified capsid proteins for enhanced delivery of parvovirus vectors.
IL251450A0 (en) Compositions and methods for silencing hepatitis b virus gene expression
AR103927A1 (en) METHOD TO IMPROVE THE ABILITY TO RESIST DNA OF VIRUSES INFECTING PLANTS
HK1248278A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
BR112019010565A2 (en) viral application of neoantigens
PT3216867T (en) Method for modifying genome sequence to introduce specific mutation to targeted dna sequence by base-removal reaction, and molecular complex used therein
MX2016016722A (en) Coronavirus.
EA201201025A1 (en) NUCLEIC ACID MOLECULES OF INFLUENZA AND VACCINES PRODUCED FROM THEM
CO2017007105A2 (en) New tilapia viruses
DK3171676T3 (en) PLASMA GENERATING DEVICE, PLASMA GENERATING SYSTEM AND METHOD OF PLASMA GENERATION
CL2016003426A1 (en) System and method for modeling and designing pulse fracture networks
CO2020001354A2 (en) Methods and compositions for treating a bleeding event in a subject suffering from hemophilia an RNA, for example, a double-stranded ribonucleic acid (rnhd), compositions targeting the serinc1 gene, and methods for using said RNA, for example, rnhd, compositions for treat a bleeding event in a subject who has hemophilia (eg, with or without inhibitors).
CU24580B1 (en) ATTENUATED VECTORS OF INFLUENZA FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES AND FOR THE TREATMENT OF ONCOLOGICAL DISEASES
CL2017003277A1 (en) Personal search index with improved privacy.
EA201690685A1 (en) COMPOSITIONS AND METHODS OF INHIBITING THE EXPRESSION OF THE ALAS1 GENE
HK1219500A1 (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof rna
HUE043096T2 (en) Method for rapid generation of an infectious rna virus
HUE055036T2 (en) Method for rapid generation of an attenuated rna virus
PL411543A1 (en) An agent increasing effectiveness of DNA vaccine directed against a virus, DNA plasmid preparation, DNA vaccine, method for obtaining modified expressive vector and the application of nucleotide sequence recognized by the agent NF kappa B.